The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619300-male-hypogonadism-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism
- The report reviews pipeline therapeutics for Male Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Male Hypogonadism therapeutics and enlists all their major and minor projects
- The report assesses Male Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Male Hypogonadism
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Male Hypogonadism Overview 9
Therapeutics Development 10
Pipeline Products for Male Hypogonadism - Overview 10
Pipeline Products for Male Hypogonadism - Comparative Analysis 11
Male Hypogonadism - Therapeutics under Development by Companies 12
Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes 14
Male Hypogonadism - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Male Hypogonadism - Products under Development by Companies 18
Male Hypogonadism - Products under Investigation by Universities/Institutes 20
Male Hypogonadism - Companies Involved in Therapeutics Development 21
Antares Pharma, Inc. 21
Clarus Therapeutics, Inc. 22
Endo Pharmaceuticals Inc. 23
EndoCeutics, Inc. 24
Ferring International Center S.A. 25
Forendo Pharma Limited 26
Lipocine Inc. 27
M et P Pharma AG 28
Merck & Co., Inc. 29
Mereo Biopharma Group Plc 30
Millennium Pharmaceuticals Inc 31
Pantarhei Bioscience BV 32
Repros Therapeutics Inc. 33
Variant Pharmaceuticals, Inc. 34
Male Hypogonadism - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
BGS-649 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
Access Report @ https://www.wiseguyreports.com/reports/619300-male-hypogonadism-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment